SENATE-BILL 4355: S.4355 - Drug Deal Disclosure Act
AI-Powered Summary
SENATE-BILL 4355 aims to enhance transparency in drug pricing by mandating the public release of drug pricing agreements, thereby empowering consumers with critical information to make informed healthcare decisions. The legislation addresses major themes of consumer rights, healthcare affordability, and corporate accountability, particularly focusing on the disclosure of pricing agreements by the Department of Health and Human Services. Key provisions include the requirement for timely disclosure, restrictions on withholding information based on reputational harm, and an obligation to report to Congress regarding any withheld information. Implementation will require the Department of Health and Human Services to establish a framework for disclosure, with a timeline that ensures timely access to information for consumers. The potential impacts include increased access to affordable medications, a shift towards greater accountability in drug pricing practices, and the balancing of transparency with the protection of proprietary information, which may raise constitutional concerns regarding the rights of drug manufacturers.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill promotes transparency in government dealings with pharmaceutical companies, which is essential for informed decision-making by individuals regarding their healthcare. This transparency can empower individuals across various demographic groups to advocate for their rights and access to affordable medications.
Key Individual Rights
- Right to Information (First Amendment)
- Equal Protection under the Law (14th Amendment)
- Due Process in Healthcare Access (14th Amendment)
Constitutional Provisions
- First Amendment
- 14th Amendment
Potential Constitutional Challenges Or Support
Challenges
- Concerns about privacy and proprietary information may arise, as pharmaceutical companies could argue that mandatory disclosure infringes on their rights to protect trade secrets.
- The potential negative impact on drug availability if manufacturers react adversely to increased transparency could raise practical concerns about access to necessary medications.
Support
- The bill reinforces democratic accountability by enhancing transparency, which is a cornerstone of a functioning democracy.
- By potentially lowering drug prices through increased competition, the bill could improve access to medications for economically disadvantaged individuals.
Summary
The Drug Deal Disclosure Act has the potential to significantly impact individual rights by promoting transparency in drug pricing, which can lead to better healthcare access and informed decision-making. While it raises some concerns regarding proprietary information and drug availability, the overall alignment with constitutional principles of transparency and equal protection supports its classification as a beneficial legislative measure.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention S. 4355 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
April 21, 2026
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat